A-Alpha Bio

A-Alpha Bio

A-Alpha Bio

AAlpha Bio is revolutionizing preclinical drug development. Our technology enables unprecedented characterization of proteinprotein interactions.
Type
B2c
Founded
2017
Raised
$1M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
$800,000
Grant - 2020
Bill & Melinda Gates Foundation
$225,000
Grant - 2018
National Science Foundation (NSF)
Team Size
1–10
Employees
$800,000 Grant
GeekWire , neurons.AI

Gates Foundation awards $800K grant to A-Alpha Bio for COVID-19 treatment research

$225,000 Grant
GeekWire

Clinical drug screening startup A-Alpha Bio awarded Small Business Innovation Research grant

GeekWire

Pre-clinical drug screening startup A-Alpha Bio wins first place at Univ. of Washington Business Plan Competition

Robotics